



Biotech Daily

Thursday September 11, 2014

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH EVEN: MEDICAL DEVELOPMENTS UP 18%
- OPTISCAN DOWN 17%**
- * **AUSBIOTECH GOLD COAST OCTOBERFEST REGISTRATION OPENS**
- * **MEDICAL DEVELOPMENTS APPOINTS GALEN UK DISTRIBUTOR**
- * **COGSTATE RECRUITMENT CONTRACT FOR ALZHEIMER'S TRIAL**
- * **REGENEUS LAUNCHES KVAX DOG CANCER VACCINE**
- * **SUN ADDS ASTHMA GENETICS TO DRUG TESTING**
- * **BLUECHIIP EX-M-D, BRETT SCHWARZ BELOW 5%**
- * **GI DYNAMICS APPOINTS DANIEL MOORE DIRECTOR**
- * **MICHAEL GRAHAM REPLACES NUSEP DIRECTOR PRAKASH PATEL**
- * **PSIVIDA ELECTS DR JAMES BARRY DIRECTOR**
- * **GENETIC TECHNOLOGIES TAKES FUND RAISING HALT TO SUSPENSION**

MARKET REPORT

The Australian stock market fell 0.51 percent on Thursday September 11, 2014 with the S&P ASX 200 down 28.2 points to 5,546.1 points. Fourteen of the Biotech Daily Top 40 stocks were up, 14 fell, six traded unchanged and six were untraded.

Medical Developments was the best, up 18 cents or 17.65 percent to \$1.20 with 62,489 shares traded.

Living Cell climbed 6.1 percent; Clinuvel and Prana were up more than five percent; Antisense and Oncosil were up more than three percent; Alchemia and GI Dynamics rose two percent or more; Benitec, Impedimed and Viralytics were up one percent or more; with Bionomics, CSL, Resmed and Sirtex up by less than one percent.

Optiscan led the falls, down 0.7 cents or 16.7 percent to 3.5 cents with 350,000 shares traded. Nanosonics lost 5.1 percent; Biotron and IDT fell four percent or more; Cellmid was down 3.6 percent; Analytica, Ellex, Mesoblast, Starpharma and Tissue Therapies shed two percent or more; Neuren, Pharmaxis and Phosphagenics fell more than one percent; with Cochlear and Psivida down by less than one percent.

AUSBIOTECH

Ausbiotech says that registration is open for its annual conference, to be held this year at Queensland's Gold Coast Convention and Exhibition centre, from October 29 to 31, 2014. Ausbiotech said that the theme for this year's national conference was "Life science equals future, jobs and exports"

The industry organization said that more than 1,000 delegates were expected at the conference including more than 150 foreign delegates.

Ausbiotech said the conference was the largest annual biotechnology event in Australia and the Asia Pacific Region and Ausbiotech 2014 would facilitate "hundreds of meetings between participants from the biotechnology, biopharmaceutical, life sciences, business, investment, research and health industries".

Ausbiotech said the conference was co-hosted with the Queensland Government, with the Millis Oration on 'The connection between medical research and business' to be delivered by Queensland Institute for Medical Research Berghofer Medical Research Institute director Prof Frank Gannon.

Ausbiotech said that other plenary speakers included the Johnson & Johnson's Janssen Pharmaceutical Companies chairman Dr Paul Stoffels, Wilson Sonsini Goodrich Rosati partner Prof Ian Edvalson, Protgen founder Prof Yongzhang Luo and Frost & Sullivan healthcare senior vice-president Rhenu Bhuller.

The industry organization said that the "ever-popular business matching program" would allow delegates to request and accept meetings with other delegates through its partnering system.

Ausbiotech said that the 2014 conference would feature several satellite events including the two-day Agriculture and Food Biotechnology Symposium.

Ausbiotech said a public forum would be held on 'Perspectives on dementia and Alzheimer's and biotechnology's role in treatments and prevention' on October 31.

For more information about the conference and to register go to: www.ausbiotechnc.org
Enquiries to events@ausbiotech.org.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says that Galen will be its exclusive distributor for its inhaled pain relief Pentrox in the United Kingdom.

Medical Developments said that the initial five-year distribution and supply agreement included a \$650,000 upfront payment on signing and additional payments on marketing authorization approval and potential future sales milestones.

The company said that the Craigavon, Northern Ireland-based Galen was part of the Almac group and a specialty pharmaceutical sales and marketing company with "a significant presence in the UK and Irish markets".

Medical Developments chief executive officer John Sharman said the agreement was "a significant achievement" as the company progressed its regulatory dossier and marketing authorization application in the UK, France, Belgium and Ireland.

Mr Sharman said the company hoped to have marketing approval in Europe by the end of 2014 and estimated that the emergency medicine market in the UK for Pentrox was about five times that of the Australia.

Medical Developments said it was negotiating with other companies to representing Pentrox in various European markets.

Medical Developments climbed 18 cents or 17.65 percent to \$1.20.

COGSTATE

Cogstate says it has a pharmaceutical company contract for its Precision Recruitment technology to assist identify and recruit patients for a phase III Alzheimer's disease study. Cogstate said the Alzheimer's disease study was the same one that it was providing Rater Training services in a separate contract worth \$7.3 million (BD: Aug 5, 2014).

The company said the additional contract provided for Precision Recruitment to be used in five of the 15 countries recruiting patients for the trial, with potential for the program to be expanded if the results from those initial countries are positive.

Cogstate said it could not disclose the financial terms of the contract "due to the success-based nature of the contract".

The company said that using Precision Recruitment potential participants were identified by the pharmaceutical company and performed tests on Cogstate's web portal.

The company said that patients would either enter the next stage of recruitment or be asked to join Cogstate's cognition registry database.

Cogstate was up half a cent or 1.85 percent to 27.5 cents.

REGENEUS

Regeneus says it has launched its Kvax canine therapeutic cancer vaccine in Australia. Regeneus said that a small amount of tumor was removed from the dog and sent to its production facility, where a personalized vaccine was created and then administered at three-week intervals over 12-weeks, stimulating the dog's immune system, helping to prevent further growth of the existing tumor, and the development of new tumors.

Regeneus veterinary business head Dr Duncan Thomson said that the "treatment could provide a new option for human cancers that are difficult to treat, as well as a follow on treatment for patients who have already been through standard treatments".

Regeneus fell half a cent or 1.6 percent to 30 cents with 1.3 million shares traded.

SUN BIOMEDICAL

Sun says it hopes to raise \$825,000 at one cent a share to research genes and immunobiological mechanisms predictive of asthma.

Previously focused on drug testing devices, Sun said that it had signed a research agreement with the Subiaco, Western Australia-based Telethon Kids Institute for asthma. Sun said it would fund the first stage of research to identify genes which had potential utility as a diagnostic and/or therapeutic target predictive of asthma.

The company said that the project would study of immune responses to house dust mite in allergic subjects with or without asthma, to determine if there was a specific pattern of immune responses associated with asthma.

Sun said that house dust mite allergy was a significant risk factor for asthma and host-immune factors were "of crucial importance to explain why only a subset of individuals exposed to such an allergen [developed] asthma".

Sun said that the study would have a two stage design with the discovery cohort consisting of 15 house dust mite allergic subjects with asthma and 15 house dust mite allergic subjects without asthma; and the validation cohort to replicate the discovery findings, consisting of a further 30 house dust mite allergic subjects, also 15 with asthma and 15 without asthma.

The company said that the project would be led by the from Telethon Kids Institute Dr Anthony Bosco,

Sun Biomedical was unchanged at one cent with 24.8 million shares traded.

BLUECHIIP

Former Bluechiip managing director Brett Schwarz says he has reduced his shareholding below the five percent substantial level.

In 2011, Mr Schwarz said that with related parties Rainbow investments and Kermet Pty Ltd and through a put-option with Mr Kirkwood he held 9,172,000 shares or 11.7 percent of the company (BD: Jun 14, 2011).

Mr Schwarz told Biotech Daily at that time that discounting the put-options he held 10.1 percent.

Today, Mr Schwarz said that he sold 1,302,000 shares for \$68,157 or 5.2 cents a share. Bluechiip was unchanged at 10.5 cents.

GI DYNAMICS

GI Dynamics says that Daniel Moore has been appointed as a director, effective from September 10, 2014.

GI Dynamics said that Mr Moore was the president and chief executive officer of Cyberonics and the appointment expanded the board to seven directors, six of whom were independent directors.

GI Dynamics Chairman Jack Meyer said that Mr Moore had led Cyberonics and commercialized a US Food and Drug Administration-approved medical device for epilepsy and depression, conditions that are typically treated with drugs.

Mr Meyer said that Mr Moore's experience would be a "valuable perspective ... as we advance our pivotal trial for Endobarrier in the US".

The company said that prior to Cyberonics, Mr Moore was with Boston Scientific for 17 years in sales, marketing and management in the US and Europe.

GI Dynamics said that Mr Moore was a director of Brainscope Co, Trivascular Technologies, Topera, Bio-Houston, the Epilepsy Foundation of Texas, the Epilepsy Foundation of America, was the immediate past-chairman of the Medical Device Manufacturers Association and served on the advisory board at the Weldon School of Biomedical Engineering at Purdue University.

The company said that Mr Moore held a Bachelor of Arts from Harvard University and a Masters of Business Administration from Boston University.

GI Dynamics was up one cent or two percent to 52 cents.

NUSEP HOLDINGS

Nusep says it has appointed Michael Graham as a non-executive director, replacing Prakash Patel, effective today.

Nusep said that Mr Graham had been involved in commercial ventures and originally qualifying as a company secretary had worked in mining, retail and services.

The company said that Mr Graham spent 10 years with the UK-based communications group WPP (formerly Wire and Plastic Products) marketing services division.

Nusep said that since 2010, Mr Graham had been the chief executive officer of Mercurien Pty Ltd, a technology company focused on telemetry for motor vehicles.

The company said that Mr Graham held a Bachelor of Arts from the University of Queensland and a post-graduate Diploma in Management from Queensland University of Technology.

Nusep was untraded at 6.7 cents.

PSIVIDA

Psivida says it has elected Dr James Barry as a director.

Psivida said that Dr Barry was currently Inspiremd's executive vice-president and chief operating officer, where he was responsible for advancing the product pipeline, managing clinical trial activities and driving the operational activities.

The company said that previously Dr Barry was the chief executive officer of Arsenal Medical, a device company focused on haemostasis and drug delivery.

Psivida said that from 1992 to 2010, Dr Barry was an executive at Boston Scientific and from 2007 to 2010 was led the company's \$US1 billion research and development effort.

The company said that Dr Barry oversaw the development of the Taxus drug eluting coronary stent, with more than \$US3 billion in first year sales.

Psivida said that Dr Barry currently served on advisory boards including the College of Biomedical Engineering at Yale University, the College of Sciences at University of Massachusetts-Lowell and the Massachusetts Life Science Center.

The company said Dr Barry received his Doctorate of Philosophy from the University of Massachusetts-Lowell and a Bachelor of Arts from the Manchester, New Hampshire-based St Anselm College.

Psivida fell two cents or 0.4 percent to \$5.02.

GENETIC TECHNOLOGIES

Genetic Technologies has requested a voluntary suspension to follow the trading halt requested on September 9, "pending an announcement ... in relation to a proposed capital raising" (BD: Sep 9, 2014).

Genetic Technologies last traded at 2.5 cents.